NuVasive Stock Forecast, Price & News

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

Is NuVasive a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive or view top-rated stocks.

What stocks does MarketBeat like better than NuVasive?

Wall Street analysts have given NuVasive a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NuVasive wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for NuVasive.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) posted its quarterly earnings results on Wednesday, July, 28th. The medical device company reported $0.60 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.43 by $0.17. The medical device company had revenue of $294.83 million for the quarter, compared to the consensus estimate of $286.17 million. NuVasive had a trailing twelve-month return on equity of 12.47% and a net margin of 0.16%.
View NuVasive's earnings history.

How has NuVasive's stock been impacted by Coronavirus?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NUVA stock has increased by 27.8% and is now trading at $63.16.
View which stocks have been most impacted by COVID-19.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its third quarter 2021 earnings guidance on Monday, September, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of -$294.80 million, compared to the consensus revenue estimate of $302.55 million.

What price target have analysts set for NUVA?

10 brokerages have issued twelve-month price targets for NuVasive's stock. Their forecasts range from $48.00 to $80.00. On average, they expect NuVasive's share price to reach $67.18 in the next year. This suggests a possible upside of 6.4% from the stock's current price.
View analysts' price targets for NuVasive or view top-rated stocks among Wall Street analysts.

Who are NuVasive's key executives?

NuVasive's management team includes the following people:

• J. Christopher Barry, Chief Executive Officer & Director (LinkedIn Profile)
• Dale Wolf, Senior Vice President-Global Operations
• Matthew K. Harbaugh, Chief Financial Officer & Executive Vice President
• Kyle Malone, VP-Clinical, Medical & Regulatory Affairs
• Ryan Donahoe, Chief Technology Officer

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Who are some of NuVasive's key competitors?

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of NUVA's competitors.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.60%), Thrivent Financial for Lutherans (2.75%), Thrivent Financial for Lutherans (2.75%), Price T Rowe Associates Inc. MD (2.40%), Dimensional Fund Advisors LP (2.30%) and Anchor Capital Advisors LLC (2.21%). Company insiders that own NuVasive stock include Gregory T Lucier, James Christopher Barry, Lucas Vitale, Massimo Calafiore, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Victory Capital Management Inc., Jennison Associates LLC, Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, Fort Washington Investment Advisors Inc. OH, Kennedy Capital Management Inc., and Fisher Asset Management LLC. Company insiders that have sold NuVasive company stock in the last year include James Christopher Barry, Lucas Vitale, and Massimo Calafiore.
View insider buying and selling activity for NuVasive or view top insider-selling stocks.

Which institutional investors are buying NuVasive stock?

NUVA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Royal Bank of Canada, Nuveen Asset Management LLC, Bridgewater Associates LP, Knights of Columbus Asset Advisors LLC, Marshall Wace LLP, Marshall Wace LLP, and Vanguard Group Inc..
View insider buying and selling activity for NuVasive or or view top insider-buying stocks.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $63.16.

How much money does NuVasive make?

NuVasive has a market capitalization of $3.26 billion and generates $1.05 billion in revenue each year. The medical device company earns $-37,150,000.00 in net income (profit) each year or $1.23 on an earnings per share basis.

How many employees does NuVasive have?

NuVasive employs 2,700 workers across the globe.

Does NuVasive have any subsidiaries?

The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, and SafePassage.

When was NuVasive founded?

NuVasive was founded in 1997.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

Where are NuVasive's headquarters?

NuVasive is headquartered at 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at (858) 909-1800 or via email at [email protected].